breast tumours
dormant-state breast cancer
cancer genomics
breast cancer patients' survival
dormant cancer cells
clinical model of estrogen receptor-positive breast cancer dormancy
extended letrozole treatment
cancer patientsâ€™ expression profiles
unique series of breast tumour biopsies
number of dynamic molecular studies of cancer treatment
neoadjuvant letrozole
clinical outcomes
study
post-treatment tumour biopsies
letrozole resistance
majority of ER
available clinical model
neoadjuvant endocrine therapy
individualized therapy
proteome-wide expression data
minority of tumours
throughput data
months
estrogen receptor alpha positive
expression profiling technologies
extended growth suppression
improved outcomes
Molecular characterisation
training
advanced integrative bioinformatics analysis of high
accordance
great competence
quality of life
death
exposure
academic aspects
fellow
cumulative incidence of recurrence
best
stable size
order
weeks
years
time
non-academic sector
multidisciplinary project
economy
metastasis
society
genome
diagnosis
steady rate
window of opportunity
knowledge